The commercial license builds on an existing research and clinical licensing agreement for select disease areas. Under the terms of the license, Crispr Therapeutics and Casebia will obtain
Pfizer expects to launch Zavicefta in additional markets outside the U.S. throughout 2017 and 2018. Zavicefta was developed in response to the urgent medical need for new antibiotics
The companies will focus on a single G protein-coupled receptor (GPCR) nominated by Daiichi Sankyo that plays a crucial role in relieving pain. Under the terms of the
No new safety signals or unexpected safety findings were seen in this long-term safety study. The profile of observed adverse events (AEs) was similar to that reported for
Orphan drug designation is granted by the FDA to investigational compounds intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect
The round includes participation by additional new investors RA Capital Management and Rock Springs Capital as well as existing investors. Proceeds from the financing will be used to
Key highlights include: Pelican was the recipient of a highly competitive $15.2m New Company Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT), which
BerGenBio’s lead candidate BGB324 is a first in class, highly selective, potent and orally available small molecule Axl kinase inhibitor in clinical development in a variety of cancer
The Company remains completely blinded to the data from this analysis. BGS-649 is a novel once weekly oral aromatase inhibitor in development as a first-line therapy for the
Aptuit and BioVersys hope that innovative approaches can address antibiotic resistance in the treatment of serious infections. BioVersys is focused on the development of small molecules interfering with
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.